Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing growth hormone efficacy: an evidence-based analysis.

Robert H Lustig1

  • 1Division of Endocrinology, Department of Pediatrics, University of California, San Francisco, CA 94143-0434, USA. rlustig@peds.ucsf.edu

Hormone Research
|November 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corporate Vectors of Chronic Disease - Using Internal Industry Documents to Craft Counterstrategies.

The New England journal of medicine·2026
Same author

Personalized Nutrition in Pediatric Chronic Diseases.

Metabolites·2025
Same author

The battle over "food addiction".

Frontiers in psychiatry·2025
Same author

Reappraisal of adverse obstetric outcomes independently associated with contemporary fertility treatment practices: a US prospective cohort study.

American journal of obstetrics and gynecology·2025
Same author

Analysis of Tanner stage in children conceived after the diagnosis of infertility: the DESCRT study.

Journal of assisted reproduction and genetics·2025
Same author

Felix A. Conte, MD, 1935-2024: The Endocrinologist's Endocrinologist.

Hormone research in paediatrics·2025
Same journal

Abstracts of the LWPES/ESPE 8th Joint Meeting Global Care in Paediatric Endocrinology, in collaboration with APEG, APPES, JSPE and SLEP. New York City, New York, USA. September 9-12, 2009.

Hormone research·2011
Same journal

Abstracts of the 47th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Istanbul, Turkey. September 20-23, 2008.

Hormone research·2011
Same journal

Abstracts of the 46th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Helsinki, Finland. June 27-30, 2007.

Hormone research·2011
Same journal

Genetic and pathogenetic aspects of Noonan syndrome and related disorders.

Hormone research·2009
Same journal

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.

Hormone research·2009
Same journal

Growth hormone and the heart in Noonan syndrome.

Hormone research·2009
See all related articles

Recombinant growth hormone (GH) therapy for GH deficiency often yields suboptimal final height. Key challenges include poor patient compliance, ineffective dosing strategies, and inadequate monitoring of treatment efficacy.

Area of Science:

  • Pediatric Endocrinology
  • Growth Hormone Therapy
  • Metabolic Disorders

Background:

  • Recombinant human growth hormone (rhGH) has been available for nearly 20 years for treating growth hormone deficiency (GHD).
  • Despite abundant supply and widespread use, achieving optimal final height in GHD patients remains a significant clinical challenge.
  • Several factors are implicated, including patient adherence, dosing regimens, and efficacy monitoring.

Purpose of the Study:

  • To review the current challenges and potential solutions for optimizing final height outcomes in growth hormone (GH)-deficient patients.
  • To critically evaluate the impact of compliance, dosing, and monitoring on treatment efficacy.

Main Methods:

  • Literature review and synthesis of existing data on recombinant growth hormone (GH) therapy.

Related Experiment Videos

  • Analysis of factors influencing treatment outcomes, including compliance, dosing strategies, and IGF-1 monitoring.
  • Discussion of the limitations of current GH delivery systems and their impact on final height.

    • Main Results:

    • Poor compliance, suboptimal dosing, and inadequate efficacy monitoring are frequently cited reasons for underachievement in final height.
    • While GH pens may improve acceptability, data on enhanced compliance are limited.
    • Current GH delivery systems have not demonstrated an increase in final height.
    • Daily or six-times-weekly dosing is more effective, but dose escalation, particularly during puberty, can advance bone age and pubertal progression, counteracting benefits.
    • Titration of GH dose based on Insulin-like Growth Factor-I (IGF-I) levels may aid final height, but increased IGF-I levels do not consistently correlate with increased height velocity.

    Conclusions:

    • Optimizing final height in GH-deficient patients remains a complex issue with unresolved challenges.
    • Further research is needed to improve compliance, refine dosing strategies, and develop effective monitoring tools for GH therapy.
    • The development of novel GH delivery systems and therapeutic approaches is crucial for enhancing treatment outcomes.